AbilityPharma announces that the World Health Organization (WHO) has recommended ABTL0812, a first-in-class oral drug for cancer treatment that causes selective death of cancer cells through autophagy...
Read moreAbilityPharma is currently completing an international Phase 2b clinical trial with its product ABTL0812 in patients with metastatic pancreatic cancer, a disease with a very low survival rate, with th...
Read moreThe biopharmaceutical company Ability Pharmaceuticals, SL today announced the inclusion of the first patients in a phase 2b clinical trial with its novel autophagy-inducer anticancer compound ABTL0812...
Read moreEl equipo ejecutivo se refuerza con la incorporación de Maribel Berges como Directora General ascendiendo Carles Domènech a la Presidencia Ejecutiva
Read moreAbilityPharma (Ability Pharmaceuticals, SL) a biopharmaceutical company developing oncology drugs, announced today that the company will release the first results of the currently ongoing phase 1/2...
Read moreAbility Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced today that it has received orphan-drug designation (ODD) for ABTL0812 from the US Food and Drug...
Read moreLa compañía biotecnológica AbilityPharma acaba de lanzar una ronda de inversión de 1.000.000 de euros a través de la plataforma de crowdfunding Capital Cell para seguir desarrollando ABTL0812, un...
Read moreAbility Pharmaceuticals SL, a biopharmaceutical company announced today that the United States Food and Drug Administration (FDA) has approved a phase 1/2 study to assess the efficacy and safety of AB...
Read moreAbility Pharmaceuticals SL, a biopharmaceutical company announced today that the United States Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application which vali...
Read moreABTL0812 es una molécula contra el cáncer "first-in-class" totalmente diferenciado y administrado por vía oral, que inhibe la vía PI3K/Akt/mTOR sin ser un inhibidor directo de las quinasas. ABTL08...
Read moreAbility Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced today that has received orphan-drug designation (ODD) for ABTL0812 from the European Medicines ...
Read moreAbility Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced today that has received orphan-drug designation (ODD) for ABTL0812 from the US Food and Drug Ad...
Read more